RenovoRx (RNXT) Expected to Post Earnings on Thursday

Key Points

• RenovoRx is expected to report Q3 2026 earnings after market close on November 5, 2026. Analysts project a loss of $0.05 per share and revenue of $1.06 million.
• In the prior quarter, RenovoRx reported a $0.05-per-share loss, beating estimates by $0.02, while revenue of $0.91 million exceeded expectations of $0.70 million. The company continues to post deeply negative margins and return on equity.
• Analyst sentiment is mixed, with RenovoRx holding a “Moderate Buy” consensus rating and an $8.50 target price, despite the stock trading near $1.43. The clinical-stage biotech is developing targeted cancer treatments using its TAMP drug-delivery platform and RenovoCath system.

RenovoRx (NASDAQ:RNXT - Get Free Report) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect RenovoRx to announce earnings of ($0.05) per share and revenue of $1.06 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.02. The firm had revenue of $0.91 million during the quarter, compared to analyst estimates of $0.70 million. RenovoRx had a negative return on equity of 135.11% and a negative net margin of 621.71%. On average, analysts expect RenovoRx to post ($0.24) EPS for the current fiscal year and ($0.12) EPS for the next fiscal year.

RenovoRx Price Performance

RenovoRx stock opened at $1.43 on Thursday. The stock has a market capitalization of $64.31 million, a price-to-earnings ratio of -4.60 and a beta of 0.98. RenovoRx has a 1-year low of $0.70 and a 1-year high of $2.59. The business has a fifty day moving average price of $1.56 and a 200-day moving average price of $1.10.

Analyst Ratings Changes

RNXT has been the subject of a number of research analyst reports. Weiss Ratings upgraded RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 2nd. Wall Street Zen downgraded RenovoRx from a "hold" rating to a "sell" rating in a report on Saturday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, RenovoRx presently has an average rating of "Moderate Buy" and a consensus target price of $8.50.

About RenovoRx

RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company's approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx's lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.